Patents are among the most straightforward intangible assets to identify — they are registered, numbered, and publicly documented. But valuing them is anything but straightforward. A patent's economic value depends not on its legal existence but on the revenue it protects, the market it covers, the strength of its claims, and the years remaining in its life.
Patent valuation is required in multiple contexts: acquisition accounting under IFRS 3, licensing negotiations, litigation damages, tax transfer pricing, portfolio management, and financing. Each context may produce a different value for the same patent — not because the methods are arbitrary, but because the premise of value (fair value, fair market value, investment value) differs.
Patent value is not determined by the cost of obtaining the patent or the novelty of the invention. It is determined by the economic benefit the patent generates — through protected revenue, licensing income, or competitive advantage. Understanding this distinction is essential for accurate valuation.
The Relief-from-Royalty method is the most commonly applied technique for patent valuation, particularly in purchase price allocations and transfer pricing. It values the patent based on the royalty payments the owner avoids by owning the patent outright rather than licensing it.
Determine the revenue generated by products or services that are covered by the patent. For broad platform patents, this may be the entire revenue of a product line. For narrow patents, it may be a specific feature or component.
Based on comparable licensing agreements, industry norms, and the patent's relative strength. Rates are expressed as a percentage of revenue.
Forecast protected revenue over the patent's remaining life, applying growth rates and considering potential challenges or design-arounds.
Apply a patent-specific discount rate. Patents carry higher risk than the overall business due to legal challenge risk, technology obsolescence, and enforcement costs.
| Industry / Technology | Typical Royalty Rate Range |
|---|---|
| Pharmaceuticals (branded drugs) | 4-10% of net sales |
| Medical devices | 3-7% |
| Software and platforms | 2-6% |
| Semiconductors | 1-4% |
| Telecommunications (FRAND) | 0.5-2.5% |
| Consumer electronics | 1-5% |
| Automotive technology | 1-4% |
| Clean energy and environmental | 2-6% |
| Chemical processes | 2-5% |
| Biotechnology | 5-15% |
Royalty rates vary enormously even within industries. The rate depends on the breadth and strength of the patent claims, the market size, the availability of non-infringing alternatives, and the negotiating leverage of both parties. Published databases (ktMINE, RoyaltyStat, Royalty Source) provide transaction-level licensing data.
The income approach values a patent based on the present value of the incremental cash flows it generates. This differs from RFR in that it measures actual profit impact rather than hypothetical royalty savings.
The income approach is particularly useful for:
A pharmaceutical company holds a patent on a drug formulation generating £30M in annual revenue with a 65% gross margin. The patent has 8 years of remaining life. The unpatented generic alternative would generate the same revenue but with a 25% gross margin (price competition). The patent's incremental profit is 40% of £30M = £12M annually. Discounted over 8 years at a 16% patent-specific rate, the patent value is approximately £48M.
The cost approach values a patent based on the cost to develop the underlying invention — R&D expenditure, personnel costs, testing, and patent prosecution fees, adjusted for obsolescence.
The cost approach almost always understates patent value because the cost of inventing something bears little relationship to its commercial worth. A £50K invention that generates £10M in annual revenue is worth far more than £50K. Use the cost approach only as a floor value or when income data is unavailable.
The value of any patent depends heavily on its strength — the likelihood that it would withstand challenge and be enforceable against infringers.
| Factor | Strong Patent | Weak Patent |
|---|---|---|
| Claim breadth | Broad independent claims covering core concepts | Narrow claims easily designed around |
| Prior art clearance | Clean search with significant novelty | Crowded field, marginal novelty |
| Jurisdictions | Granted in key markets (US, EU, China, Japan) | Single jurisdiction |
| Prosecution history | Clean prosecution, no narrowing amendments | Significant amendments during examination |
| Remaining life | 10+ years remaining | Less than 5 years |
| Enforceability | No validity challenges pending | Under review or post-grant challenge |
| Market coverage | Covers dominant product configurations | Covers niche or declining configurations |
| Design-around difficulty | No viable non-infringing alternatives | Easy to engineer around |
A patent with broad claims, long remaining life, and no viable design-arounds in a large market is worth orders of magnitude more than a narrow patent in a declining market with 2 years remaining. The legal existence of the patent is only the starting point — the economic analysis is what determines value.
Most companies own patent portfolios rather than individual patents. Portfolio valuation requires additional considerations:
For large portfolios (100+ patents), individual valuation is impractical. Practitioners typically:
In a purchase price allocation, patents must be valued at fair value under IFRS 3. RFR is the standard method. The useful life is the remaining legal life or the estimated economic life, whichever is shorter. Amortisation begins from the acquisition date.
When licensing patents, the valuation establishes the range for negotiation. The licensor's floor is the cost approach value; the licensee's ceiling is the income approach value. The agreed royalty rate falls somewhere between, reflecting relative bargaining power.
Patent infringement damages are typically calculated using either:
Intercompany patent transfers must be priced at arm's length. Tax authorities (HMRC, IRS) scrutinise transfer pricing for IP with increasing rigour. The OECD Transfer Pricing Guidelines specifically address intangible assets, and the DEMPE framework (Development, Enhancement, Maintenance, Protection, Exploitation) governs how value is allocated.
Patent valuation is not exclusively for large corporations and pharmaceutical companies. Startups and SMEs with granted patents often underestimate the economic value of their IP — and fail to leverage it in fundraising, licensing, and exit negotiations.
The cost of obtaining a patent (typically £15K-£50K for a single jurisdiction grant) bears no relationship to its economic value. A £20K patent protecting a product generating £5M in annual revenue may be worth £2M+ under the RFR method. The filing cost is irrelevant to the valuation.
Several trends are reshaping how patents are valued:
Whether you own a single patent or a portfolio of hundreds, understanding the economic value of your IP is essential for strategic decision-making, licensing, and exit planning.
Ivan Gowan is the Founder and CEO of Opagio. With 25 years in financial technology, he has direct experience building and protecting technology IP across regulated financial markets. He leads Opagio's mission to make intangible assets — including intellectual property — visible, measurable, and actionable. Meet the team.
A practical guide to the six core methods for valuing intangible assets: Relief-from-Royalty, MPEEM, With-and-Without, Cost, Income, and Market approaches. Includes when to use each method and worked examples.
Read more →A comprehensive guide to brand valuation covering Relief-from-Royalty, income premium, and cost approaches. Includes industry royalty rates, real-world examples, and best practice for brand valuation in M&A, licensing, and strategic planning.
Read more →AI-enabled companies trade at 25-40% higher multiples than peers, but not all AI capability is created equal. This article examines what drives the AI valuation premium, how to assess whether it is justified, and what happens when the premium unravels.
Read more →Get the latest insights on intangible asset growth and productivity delivered to your inbox.
Book a free consultation to see how the Opagio Growth Platform can help your business.